
|Videos|June 15, 2022
A US-Based, Injectables-Focused CDMO with Available Capacity and End-to-End Capabilities
Author(s)August Bioservices
Ryan Downey, Director of Customer Operations, outlines August Bioservices’ capabilities for its customers and what it means to work with them.
- They focus on sterile injectables in multiple container sizes from vials to syringes to flexible IV bags— coupled with an analytical services department.
- The current CDMO market is constrained for those who need the capacity to start their innovative work, which is where August Bioservices comes in.
- With robust tools and a strong team, they can solve difficult challenges with formulation, commercial configuration, the timing of a project, and analytical characterizations.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Trending on Pharmaceutical Technology
1
Industry Outlook 2026: Trends Transitioning from 2025 into 2026
2
Amgen Acquires UK Biotech Dark Blue Therapeutics
3
Medable Presents AI Agent for Automating Trial Master File Processes at JP Morgan Healthcare Conference
4
Genetic Medicines Project Gets Funding from UKRI Innovate UK and Canadian NRC IRAP
5




